MiRNA therapy for Intestinal cancer: MiRNA-1976 increases the expression of DNA Sensor AIM2 and inhibits expansion of tumor-initiating intestinal stem cell population via up regulation of its target gene, 7/August/2016, 3.24 pm

Small RNA-based therapy for pulmonary arterial hypertension: MiRNA-491-5p inhibits the development of pulmonary arterial hypertension via down regulation of its target gene Notch3, 7/August/2016, 2.58 pm
August 7, 2016
MiRNA-497 inhibits the expression of Ribosomal protein S6 kinase 1 (p70S6 Kinase) and extends mammalian life span via down regulation of its target gene, 7/August/2016, 3.35 pm
August 7, 2016
Show all

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Undisclosed information: How MiR-1976  increases the expression of tumor suppressor AIM2.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/


A recent study from the Department of Immunology, St. Jude Children’s Research Hospital, Memphis, TN 38105, USA shows that:  “Critical Role for the DNA Sensor AIM2 in Stem Cell Proliferation and Cancer”. This study was published in the 17 June 2015 issue of the journal “Cell” (the number 1 research journal in “General biology” with an Impact factor of 33.16) by Prof. Thirumala Devi Kanneganti, Si Ming Man and others. 

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: MiRNA therapy for Intestinal cancer: MiRNA-1976 increases the expression of DNA Sensor AIM2 and inhibits expansion of tumor-initiating intestinal stem cell population via up regulation of its target gene


Significance: 

Given that (1)  more than 1 million people every year worldwide are affected by Intestinal cancer; (2) the number of deaths has had increased from 490,000 in 1990 to 715,000 in 2010; (3) Intestinal cancer is the second and third most frequent cause of cancer in women and men, respectively; (4) Intestinal cancer is more common in developed countries than in developing countries; and (5) the global economic cost spent for Intestinal cancer treatment is enormous, there is an urgent need to find: (1) a cheaper alternative to the existing expensive drugs; and (2) a  side-effect-free drug.

A number of studies suggests that immune sensor Absent in Melanoma 2 (AIM2) is mutated in colorectal cancer. However, the significance of which is far from clear. Prof. Thirumala Devi Kanneganti’s research team has recently shown that AIM2 protects against colorectal cancer via inhibition of tumor-initiating intestinal stem cell proliferation.

7Oct2015-9

Figure 1 MiR-1976 inhibits uncontrolled proliferation of tumor-initiating intestinal stem cells and the progression of colorectal cancer via up regulation of AIM2 (Click to enlarge picture)

This study suggests that MiR-1976, by decreasing the expression of its target geneit may increase the expression of tumor suppressor AIM2. Thereby, it may: (1) inhibit uncontrolled proliferation of tumor-initiating intestinal stem cells; (2) decrease the population of dysbiotic gut microbiota; and (3) prevent colorectal cancer. Thus, pharmacological formulations encompassing “MiR-1976  activators may be used to inhibit the progression of colorectal cancer.

* Research cooperation


CitationBoominathan, L.,  MiRNA therapy for Intestinal cancer: MiRNA-1976 increases the expression of DNA Sensor AIM2 and inhibits expansion of tumor-initiating intestinal stem cell population via up regulation of its target gene, 7/August/2016, 3.24 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

Comments are closed.